Pharma Must "Continue to Take Chances" In Policy World: Merck VP's Parting Advice
This article was originally published in RPM Report
A conversation with Merck VP-global public policy Ian Spatz about the challenges and opportunities facing industry amid the changes in Washington.
You may also be interested in...
As the presidential race heats up, health care executives say they have many reasons to be excited–and nervous. Boston Consulting Group reviews an industry-wide survey on the implications of the candidates’ health care proposals for the pharma and device industries.
The hot new buzzword with policymakers is comparative clinical effectiveness, and everyone has an idea on how to make it work. But major questions remain: what might a national effort look like? And will payors use it to restrict access to new drugs?
Support for reimportation of lower-priced drugs from outside the US has been a rallying point for Democratic critics of the drug industry for almost a decade. But there are signs that some influential Democrats now view it as a distraction from the real target-cutting drug costs here.